


## Timing of Potential HIV Acquisition in People Prescribed HIV PrEP


David H. Spach, MD Professor of Medicine Division of Allergy and Infectious Diseases University of Washington

Last Updated: January 4, 2024




Time










Time

While taking HIV PrEP,


ALC: NO ALC: ALC: NO



#### Time




3






#### HIV Acquisition Prior to Starting HIV PrEP





#### HIV Acquisition Prior to Starting HIV PrEP






National HIV PrEP Curriculum

## HIV Antibody Response After HIV Acquisition

Seroconversion Window Period




Days Following HIV Acquisition




## HIV p24 Antigen Testing: Time to Positive Test

Window for HIV p24 antigen






## HIV RNA Testing: Time to Positive Test






## HIV Testing: Time to Positive Test









#### HIV Acquisition While Receiving Oral Daily HIV PrEP

HIV


Oral HIV PrEP Medication
Period with risk for HIV infection


**Taking Daily Oral HIV PrEP** 



National HIV PrEP Curriculum

#### HIV Acquisition While Receiving Oral Daily HIV PrEP






# 

#### **Taking Daily Oral HIV PrEP**




National HIV PrEP Curriculum

### HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP






### HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP






### HIV Acquisition While Receiving CAB-LA for HIV PrEP






### HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP






### HIV Acquisition While Receiving Injectable Cabotegravir for HIV PrEP







#### Time



3

Oral HIV PrEP Medication
Period with risk for HIV infection




3-7 days




**Taking HIV PrEP** 

**HIV PrEP Discontinued** 











The production of this **National HIV PrEP Curriculum** *Mini-Lecture* is supported by Grant U62PS924588 from the Centers for Disease Control and Prevention (CDC) and U10HA32104 from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS). Its contents are solely the responsibility of the University of Washington IDEA Program and do not necessarily represent the official views CDC, HRSA, or HHS. This project is led by the University of Washington Infectious Diseases Education & Assessment (IDEA) Program.



